Risk stratification of patients with locally aggressive differentiated thyroid cancer

B. Riemann; J. A. Krämer; K. W. Schmid; H. Dralle; M. Dietlein; H. Schicha; C. Sauerland; T. Frankewitsch; O. Schober; for the MSDS study group

doi:10.3413/nukmed-0302

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2010; 49(03): 79-84
DOI: 10.3413/nukmed-0302

Original article

Schattauer GmbH

Risk stratification of patients with locally aggressive differentiated thyroid cancer

Results of the MSDS trialRisikostratifizierung von Patienten mit lokal aggressiven differenzierten SchilddrüsenkrebsErgebnisse der MSDS-Studie

B. Riemann

¹Department of Nuclear Medicine, University Hospital, Muenster, Germany

,

J. A. Krämer

¹Department of Nuclear Medicine, University Hospital, Muenster, Germany

,

K. W. Schmid

²Institute of Pathology and Neuropathology, University Hospital of Essen, University of Duisburg-Essen, Germany

,

H. Dralle

³Department of General Surgery, University Halle-Wittenberg, Germany

,

M. Dietlein

⁴Department of Nuclear Medicine, University Cologne, Germany

,

H. Schicha

⁴Department of Nuclear Medicine, University Cologne, Germany

,

C. Sauerland

⁵Department of Medical Informatics and Biomathematics, University Muenster, Germany

,

T. Frankewitsch

⁶IT-Center – Research and Education, University Muenster, Germany

,

O. Schober

¹Department of Nuclear Medicine, University Hospital, Muenster, Germany

,

for the MSDS study group

› Author Affiliations

Abstract

Summary

The Multicentre Study Differentiated Thyroid Cancer (MSDS) collective represents a well defined group of patients with locally aggressive thyroid carcinomas (pT4; AJCC/UICC 1997). The aim of the present study was to compare the survival of patients with minimum and extensive extrathyroidal growth according to the new AJCC/UICC TNM staging system 2009. Patients, methods: The followup data of 347 patients were analysed. Patients were reclassified according to the current AJCC/UICC 2009 classification. The event-free and overall survival was evaluated using Kaplan-Meier analysis. In addition, postoperative complications and status of disease were documented. Results: 327 patients were assigned to stage pT3 and 20 patients to stage pT4a, respectively. Median follow-up was 6.1 years (range 0.04–9.8 years). 92.5% of patients reached complete remission. There were 7.8 % recurrences in the thyroid bed, in locoregional lymph nodes and/or in distant sites. The overall survival was >98% both in pT3 and pT4a patients (p = n. s.). In contrast, the event-free survival was significantly less favourable in pT4a patients (p < 0.001). Using multivariate analysis the following parameters were significant predictors of event-free survival: histological tumour type, degree of extrathyroidal extension and nodal metastasis (p < 0.05). Conclusions: The MSDS patients with locally aggressive differentiated thyroid cancer showed an excellent overall survival during a median follow-up of 6.1 years. According to the current AJCC/UICC 2009 classification, pT3 patients with minimal extra thyroidal extension revealed a significantly better event-free survival than pT4a patients with extensive extrathyroidal growth.

Zusammenfassung

Die Multizenter Studie Differenziertes Schilddrüsenkarzinom (MSDS) umfasst eine präzise definierte Gruppe von Patienten mit lokal aggressiven Schilddrüsenkarzinomen (pT4; AJCC/ UICC 1997). Ziel war es, das Überleben der Patienten mit minimalem und ausgedehnten extrathyreoidalen Wachstum nach der neuen AJCC/UICC TNM Klassifikation von 2009 zuvergleichen. Patienten, Methodik: Die Daten von 347 Patienten wurde ausgewertet. Dazu wurden die Patienten nach der neuen AJCC/ UICC TNM Klassifikation von 2009 reklassifiziert. Mittels Kaplan-Meier Analyse wurden das Ereignis-freie und Gesamt-Überleben evaluiert. Zusätzlich wurden die perioperativen Komplikationen und der Status der Erkrankung dokumentiert. Ergebnisse: 327 Patienten wurden dem Stadium pT3 und 20 Patienten dem Stadium pT4a zugeordnet. Der mediane Nachsorge-Zeitraum betrug 6.1 Jahre (0.04–9.8 Jahre). 92.5% der Patienten erreichten eine komplette Remission. Bei 7.8 % der Patienten fanden sich Rezidive im Schilddrüsenbett, den lokoregionalen Lymphknoten und/oder Fernmetastasen. Das Gesamt-Überleben betrug sowohl für Patienten mit pT3– als auch pT4a-Tumoren >98% (p = n. s.). Im Gegensatz dazu war das Ereignis-freie Überleben der pT4-Patienten signifikant schlechter (p < 0.001). Nach multivariater Analyse waren die folgenden Parameter signifikante Prädiktoren des Ereignis-freien Überlebens: Histopathologie, Ausmaß des extrathyreoidalen Wachstums und Lymphknonten-Metastasierung (p < 0.05). Schlussfolgerungen: Während einer medianen Nachsorge von 6.1 Jahren zeigten die MSDS Patienten mit lokal aggressiven differenzierten Schilddrüsenkarzinomen ein exzellentes Gesamt-Überleben. Nach der aktuellen AJCC/UICC Klassifikation von 2009 wiesen Patienten mit pT3-Tumoren und minimalem extrathyreoidalen Wachstum ein signifikant besseres Ereignis-freies Überleben auf als Patienten mit pT4-Tumoren und ausgedehnten extra thyreoidalen Tumoranteilen.

Keywords

Thyroid carcinomas - risk stratification - MSDS trial

Schlüsselwörter

Schilddrüsenkrebs - Risikostratifizierung - MSDS

Full Text

References

References
1 Biermann M, Schober O. GCP-compliant management of the Multicentric Study Differentiated Thyroid Carcinoma (MSDS) with a relational database under Oracle 8i. Inform Biom Epidemiol Med Biol 2002; 33: 441-459.
2 Biermann M, Pixberg MK, Schuck A. et al. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 2003; 42: 244-250.
3 Biermann M, Pixberg M, Riemann B. et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer. Nuklearmedizin 2009; 48: 89-98.
4 Byar DP, Green SB, Dor P. et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15: 1033-1041.
5 Cooper DS, Doherty GM, Haugen BR. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
6 Dralle H, Sekulla C, Haerting J. et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 2004; 136: 1310-1322.
7 Gimm O, Brauckhoff M, Thanh PN. et al. An update on thyroid surgery. Eur J Nucl Med Mol Imaging 2002; 29: S447-S452.
8 Gospodarowicz MK, Miller D, Groome PA. et al. The process for continuous improvement of the TNM classification. Cancer 2004; 100: 1-5.
9 Ito Y, Tomoda C, Uruno T. et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 2006; 30: 780-786.
10 Ito Y, Tomoda C, Uruno T. et al. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg Today 2006; 36: 12-18.
11 Ito Y, Miyauchi A, Jikuzono T. et al. Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J Surg 2007; 31: 838-848.
12 Jukkola A, Bloigu R, Ebeling T. et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. En- docr Relat Cancer 2004; 11: 571-579.
13 Lerch H, Schober O, Kuwert T. et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075.
14 Pacini F, Schlumberger M, Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
15 Riemann B, Schober O. MSDS study group. Are “high-risk” patients with differentiated thyroid cancer “healthy patients”?. Nuklearmedizin 2008; 47: 179-180.
16 Schmid KW, Wittekind C. Die missglückte Klassifikation. Pathologe 2003; 24: 338.
17 Schuck A, Biermann M, Pixberg MK. et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol 2003; 179: 832-839.
18 Sherman SI, Brierley JD, Sperling M. et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83: 1012-1021.
19 Sobin LH, Wittekind C. Thyroid gland – rules for classification. In: Sobin LH, Wittekind C. (eds) UICC TNM classification of malignant tumors. New York: Wiley-Liss; 1997: 47-50.
20 Sobin LH, Wittekind C. Thyroid gland - rules for classification. In: Sobin LH, Wittekind C. (eds) UICC TNM classification of malignant tumors. New York: Wiley-Liss; 2002: 52-56.
21 Sobin LH, Gospodarowicz MK, Wittekind C. Thyroid gland – rules for classification. In: Sobin LH, Gospodarowicz MK, Wittekind C. (eds) UICC TNM classification of malignant tumors. New York: Wiley-Liss; 2009: 58-62.
22 Verburg FA, Mäder U, Kruitwagen CL. et al. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol. 2009 DOI 10.1111/j.1365-2265.2009.03734.
23 Voutilainen PE, Siironen P, Franssila KO. et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res 2003; 23: 4283-4288.
24 Wittekind C, Greene FL, Henson DE. et al. A commentary on uniform use. In: Wittekind C, Greene FL, Henson DE. et al. (eds) TNM Supplement. New York: Wiley-Liss; 2003: 138.